Glioblastoma Changes More Than the Brain: A Surprising Effect on the Skull and Bone Marrow
In this article
Glioblastoma Erodes Skull Bone and Alters the Immune Response: A New Treatment Paradox
A striking study published in October 2025 in Nature Neurosciencerevealed that the most aggressive brain tumor, glioblastoma (GBM), causes physical erosion (resorption) of skull bone and manipulates immune-cell production in skull marrow. More importantly, standard drugs used to prevent this bone loss (bisphosphonates, etc.) were shown to potentially accelerate tumor progression.
Key Message: GBM thins the skull bone, opening immune channels for itself. However, trying to prevent this bone loss (with zoledronic acid, etc.) may paradoxically make the tumor more aggressive and promote resistance to immunotherapy.
1) Why Does the Study Matter?
For many years, we thought glioblastoma was a disease confined to the brain parenchyma. This study, however, demonstrated that the tumor actively changes the skull bone (calvarium) immediately above it and the bone marrow within it. Skull marrow is a critical reservoir supplying monocytes and neutrophils to the brain.
2) What Happens in the Skull?
The study demonstrated the following in both mouse models and CT scans of GBM patients:
- Bone Thinning: The tumor activates osteoclasts, thinning the skull.
- New Channels: The number and diameter of microchannels extending from the skull to the brain increase. These channels act as a highway through which the tumor attracts immune cells, particularly neutrophils.
3) How Does the Immune Landscape Change?
Changes in cell populations in skull marrow (scRNA-seq data):
Myeloid Skewing: GBM shifts skull marrow toward "myelopoiesis" (myeloid-cell production). Inflammatory neutrophils increase, while B cells, a stronghold of adaptive immunity, decrease dramatically.
4) The Treatment Paradox: Are Bone Drugs Harmful?
The study's most striking clinical finding was this: when researchers tried to stop skull thinning using Zoledronic Acid or Anti-RANKL agents:
1. Bone density improved.
2. BUT tumor progression accelerated.
3. The survival benefit of anti-PD-L1 immunotherapy disappeared.
Clinical Implications
Is Glioblastoma a "Systemic" Disease?
Yes. This study shows that GBM is not confined to the brain; it remotely controls bone marrow and the systemic immune response.
Should Bone-Protective Drugs Be Stopped?
This study suggests that combining bisphosphonates with immunotherapy, particularly in patients with mesenchymal-subtype GBM, could be risky , because these drugs cause tumor-supporting neutrophils to remain in the environment.
Skull vs. Femoral Marrow
| Feature | Skull Marrow | Femoral Marrow |
|---|---|---|
| Tumor Effect | Direct & Rapid | Less Pronounced & Slow |
| Neutrophils | Very Large Increase | Moderate Increase |
| B Cells | Severe Loss (90%+) | Moderate Loss |
DROZDOGAN Academy Commentary
This study (Dubey et al., 2025) challenges established thinking in oncology practice. Agents we have safely used for years to prevent bone metastases may, in a specific tumor such as glioblastoma, act as a shield protecting the tumor microenvironment . Particularly in immunotherapy studies, we must remember that patients' concurrent use of bone-modifying agents may affect outcomes.
Source: Dubey A, et al. Brain tumors induce widespread disruption of calvarial bone and alteration of skull marrow immune landscape. Nature Neuroscience. 2025 Oct;28:2231–2246.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.